Comment
doi: 10.1016/S2352-3026(19)30136-X.
Epub 2019 Jul 8.
Will GALEN become more RELEVANT?
Affiliations
- PMID: 31296424
- DOI: 10.1016/S2352-3026(19)30136-X
Item in Clipboard
Comment
Will GALEN become more RELEVANT?
Lancet Haematol.
2019 Aug.
No abstract available
Comment on
-
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296423 Clinical Trial.
Similar articles
-
Next-generation therapy for follicular lymphoma.Blood. 2018 Oct 4;132(14):1465-1467. doi: 10.1182/blood-2018-08-868117. Blood. 2018. PMID: 30287467 No abstract available.
-
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7. Cancer. 2014. PMID: 24122387 Clinical Trial.
-
Lenalidomide for the treatment of B-cell lymphoma.Expert Opin Investig Drugs. 2016 Sep;25(9):1103-16. doi: 10.1080/13543784.2016.1208170. Epub 2016 Jul 22. Expert Opin Investig Drugs. 2016. PMID: 27414850 Review.
-
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.Ann Hematol. 2016 Oct;95(11):1917-8. doi: 10.1007/s00277-016-2771-2. Epub 2016 Jul 30. Ann Hematol. 2016. PMID: 27473194 No abstract available.
-
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Best Pract Res Clin Haematol. 2012. PMID: 22687454 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
